Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CCR1 | P32246 | 2/20 | 0.50 |
| ▸ | CCR5 | P51681 | 2/20 | 0.50 |
| ▸ | CCR8 | P51685 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29925695 | 1.00 | TGFBR1 (0.56) | TGFBR1KDM4ELMNACYP1A2CCR1 | |
| SCHEMBL12663368 | 0.98 | TGFBR1 (0.55) | TGFBR1KDM4ELMNACYP1A2CCR1 | |
| SCHEMBL21988523 | 0.89 | TGFBR1 (0.51) | TGFBR1KDM4ELMNACYP1A2CCR1 | |
| SCHEMBL31400215 | 0.89 | TGFBR1 (0.51) | TGFBR1KDM4ELMNACYP1A2CCR1 | |
| SCHEMBL15748502 | 0.86 | TGFBR1 (0.49) | TGFBR1KDM4ELMNACYP1A2CCR1 | |
| SCHEMBL31039987 | 0.85 | TGFBR1 (0.51) | TGFBR1KDM4ELMNACYP1A2CCR1 | |
| SCHEMBL20023732 | 0.85 | CYP1A2 (0.47) | TGFBR1KDM4ELMNACYP1A2CCR1 | |
| SCHEMBL19862540 | 0.85 | CYP1A2 (0.47) | TGFBR1KDM4ELMNACYP1A2CCR1 | |
| SCHEMBL2424951 | 0.85 | CYP1A2 (0.47) | TGFBR1KDM4ELMNACYP1A2CCR1 | |
| SCHEMBL27736665 | 0.85 | CYP1A2 (0.47) | TGFBR1KDM4ELMNACYP1A2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115630-A1 | METAL COMPLEXES | UDC IRELAND LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-12180233-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-12-31 | — | — | US | disclosed |
| CN-111699192-B | Metal complex | UDC爱尔兰有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11795159-B2 | Compounds for the treatment of SARS | PURDUE RESEARCH FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795159-B2 | Compounds for the treatment of SARS | PURDUE RESEARCH FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20230134932-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20090105279-A1 | Antiviral protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099096-A1 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC | 2008-08-14 | — | — | US | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| WO-2007140284-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12180233-B2 | Metal complexes | IMMT, MCU, SOD1 | TGFBR1 3128/4885KDM4E 4470/4885LMNA 4756/4885 |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | TGFBR1 4699/4885KDM4E 1855/4885LMNA 4767/4885 |
| US-20250115630-A1 | METAL COMPLEXES | IMMT, MCU, SOD1 | TGFBR1 3128/4885KDM4E 4470/4885LMNA 4756/4885 |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | TGFBR1 1612/4885KDM4E 2584/4885LMNA 2692/4885 |
| US-20230134932-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | TGFBR1 4176/4885KDM4E 710/4885LMNA 2647/4885 |
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFKP, PF4, P2RY4 | TGFBR1 2562/4885KDM4E 2325/4885LMNA 2530/4885 |
| US-20090105279-A1 | Antiviral protease inhibitors | ACE, TMPRSS15, MME | TGFBR1 3797/4885KDM4E 1726/4885LMNA 2818/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | TGFBR1 2471/4885KDM4E 1169/4885LMNA 4536/4885 |
| US-11795159-B2 | Compounds for the treatment of SARS | ACE2, ACE, SARS1 | TGFBR1 4861/4885KDM4E 3407/4885LMNA 2592/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | TGFBR1 1195/4885KDM4E 4007/4885LMNA 1851/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | TGFBR1 2471/4885KDM4E 1169/4885LMNA 4536/4885 |
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | ACE2, ACE, SARS1 | TGFBR1 4861/4885KDM4E 3407/4885LMNA 2592/4885 |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | TGFBR1 1577/4885KDM4E 2775/4885LMNA 3156/4885 |
| US-20090099096-A1 | AZA-peptide protease inhibitors | DNPEP, ANPEP, PEPD | TGFBR1 3708/4885KDM4E 515/4885LMNA 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.